GlassScriptPhysician profile
Harlee A Fried
NPI 1275525040
$4,463.52
in general payments reported to CMS, 2019-2025
25 companies · $812 in 2025
The $812 reported for 2025 was more than what 81% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $243 · 2021: $95.56 · 2022: $714 · 2023: $1,080 · 2024: $935 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.47 | 2019-2024 | |
| Incyte Corporation | $745.16 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $730.80 | 2023-2024 | Sotyktu |
| Pfizer INC. | $335.61 | 2019-2025 | |
| Genzyme Corporation | $304.57 | 2020-2025 | |
| Leo Pharma INC. | $213.54 | 2019-2023 | Adbry |
| Lilly USA, LLC | $181.32 | 2019-2024 | Taltz, Ebglyss |
| Sandoz INC. | $169.53 | 2019-2020 | |
| Amgen INC. | $138.75 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $125.92 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $93.70 | 2023 | Vtama |
| Janssen Biotech, INC. | $78.44 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Biofrontera INC. | $70.02 | 2022 | |
| Organon LLC | $63.65 | 2025 | Vtama, Nexplanon |
| Ucb, INC. | $60.37 | 2024-2025 | Bimzelx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $58.18 | 2019-2025 | Winlevi, Absorica Ld |
| Almirall LLC | $55.66 | 2019-2023 | Seysara |
| Novartis Pharmaceuticals Corporation | $53.79 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.53 | 2019-2023 | Duobrii, Arazlo, Jublia |
| Arcutis Biotherapeutics, INC. | $32.76 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $28.26 | 2022 | |
| Verrica Pharmaceuticals INC. | $20.25 | 2023 | Ycanth |
| Mission Pharmacal Company | $14.25 | 2019 | |
| Celgene Corporation | $12.89 | 2019 | |
| Vyne Pharmaceuticals INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harlee Fried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.